PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
The NIH, CDC, and FDA invite US small businesses to submit SBIR grant applications for R&D projects, excluding clinical trials.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: September 5, 2024 | January 5, 2025 | April 5, 2025 | September 5, 2025
Funding Amounts: Phase I: up to $306,872 (6 months) | Phase II: up to $2,045,816 (2 years); higher budgets possible for select topics
Summary: Supports US small businesses in R&D projects aligned with NIH, CDC, and FDA missions; clinical trials are not allowed under this solicitation.
Key Information: Updated March 31, 2025 to align with agency priorities; review the full announcement before applying.
Description
This opportunity invites eligible US small businesses to apply for Small Business Innovation Research (SBIR) grants to support research and development projects that align with the missions of the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). The program aims to stimulate technological innovation, meet federal R&D needs, and increase commercialization of innovations developed with federal funding. Projects must not include clinical trials under this solicitation.
SBIR grants are available for Phase I (feasibility and proof of concept), Phase II (full R&D), Fast-Track (combined Phase I/II), Direct to Phase II (NIH only), and Phase IIB (NIH only, for further development beyond Phase II). The program covers a broad range of health, biomedical, and related research topics. Applicants are encouraged to review the SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA for specific areas of interest.
